SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples post-earnings decline is centered on guidance for weaker gross margins as memory costs rise, despite stronger-than-expected quarterly results. Traders are split between viewing the drop as an overreaction to a solid iPhone-led quarter and worrying that margin pressure, slower growth, and valuation leave little room for disappointment.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs quarterly report is in focus after Intels weak outlook helped trigger a broader semiconductor selloff and weighed on AMD shares. Traders are divided over whether AI and data-center growth and strong guidance can reassure investors, or whether valuation concerns and cautious chip-sector sentiment will overshadow the results.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 trial reaching its prespecified 80th event has triggered final analysis, with traders focused on the pending GPS topline results and a possible SLS009 update. The sharp selloff has prompted some investors to buy or hold ahead of the data, while others see the decline as a warning of possible trial weakness; claims of manipulation, dilution, or leaked results remain speculation.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs strong Q3 results and raised outlook drew attention, but shares fell as traders questioned whether rapid growth could justify the stocks high valuation. Bulls pointed to accelerating commercial AI adoption, while bears focused on lofty expectations and slower growth in contract value.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned stock-and-bond financing for its AI infrastructure buildout is driving the selloff, with traders focused on shareholder dilution, rising debt and whether the spending will generate returns. Some argue the financing was previously outlined and could limit future fundraising, while others see its timing as a warning about Oracles leverage and AI investment risks.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

SLV is drawing attention amid a steep silver-price selloff after a dramatic run-up, with traders reacting to persistent declines and questioning where support may hold. The community is split between bearish calls for further losses and dip buyers expecting an oversold rebound; some blame rate and yield pressures or technical selling, while claims of market manipulation remain speculation.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A strong fiscal Q1 report and raised FY27 outlook, supported by demand for Aehrs AI-chip burn-in testing systems, are driving attention. Bulls see the results as evidence of growth, while others question the stocks valuation and worry that broader market weakness could blunt the reaction.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDBs CEO departure to Meta, announced immediately before Investor Day, sparked a sharp selloff and volatile trading. Traders are split between viewing the leadership uncertainty as a lasting risk and seeing the drop as an overreaction, pointing to reaffirmed guidance and former CEO Dev Ittycherias return as interim chief.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,883,313.16514313 with 590,206,315.78603745 in circulation. The last known price of Solana is 92.37097662 USD and is down -1.79 over the last 24 hours. It is currently trading on 1189 active market(s) with $2,843,805,655.98 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solanas slide amid broader crypto weakness is driving discussion, with traders watching technical support and warning of further downside. Others view the pullback as a buying opportunity and say they are accumulating and staking, leaving sentiment divided.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA accelerated approval of Inovios competing RRP treatment has intensified concerns about competition for Precigens PAPZIMEOS and accompanied a sharp selloff. Traders debate whether the rivals dosing regimen will draw patients away or whether PAPZIMEOSs commercial head start, full approval, and reported efficacy will help it retain an advantage.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its third quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 5, 2026. Individuals interested in participating in the call should dial (833) 461-5787 (U.S.) or (585...

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief...

Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?

IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.

Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET. A live webcast of Ironwoods fireside chat will be accessible through the Investors...

Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised

IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.

Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of +19.23% and -5.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing lifechanging therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance. Throughout the first half of...

Ironwood Pharmaceuticals, Inc. is a biotechnology company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

Why Did Ironwood Pharmaceuticals Stock Skyrocket Today?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The outlook assumes net sales for Linzess will be between $1.125 billion and $1.175 billion in FY2026.</li><li>U.S. FDA had approved Ironwood’s Linzess capsules for pediatric patients, in November.</li><li>Linzess is the first treatment approved for the irritable bowel syndrome with constipation in pediatric patients.</li></ul>Shares of Ironwood Pharmaceuticals (<a href="https://stocktwits.com/symbol/IRWD">IRWD</a>) jumped more than 38% in premarket trading on Friday after its FY2026 guidance came in above expectations, boosted by higher sales of its drug Linzess, which is used to treat constipation.The biotechnology company said it expects FY2026 revenue in the range of $450 million to $475 million, higher than analyst expectations of $319.5 million, according to data from Fiscal.ai.&nbsp;The outlook assumes net sales of Linzess will be between $1.125 billion and $1.175 billion in FY2026, driven by improved net price and low-single-digit demand growth, the company said.&nbsp;“We believe our full-year 2026 guidance demonstrates the significant progress we’ve made to deliver on these priorities to help drive value for shareholders moving forward,” it stated.&nbsp;<h2 class="st-heading-2">Linzess’ Potential</h2>In November, the U.S. Food and Drug Administration approved Ironwood’s Linzess capsules for pediatric patients aged seven and older with irritable bowel syndrome with constipation.Linzess is the first treatment approved for the disease in pediatric patients, the FDA had said at the time. Irritable bowel syndrome with constipation (IBS-C) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain associated with infrequent, hard-to-pass stools. The contributing factors to the condition are typically multiple.Linzess is already approved for the treatment of adult patients with the condition. The FDA had noted that the safety and efficacy of Linzess were similar in clinical studies for both adults and pediatric patients.“Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an effort to strengthen our financial position and maintain compliance with debt covenants over the coming quarters,” said Tom McCourt, chief executive officer of Ironwood. “We expect higher net sales in 2026 for LINZESS year-over-year,” he added.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around IRWD trended in ‘bullish’ territory amid ‘high’ message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:632/64;" src="https://news.stocktwits-cdn.com/irwd_2_PNG_f7f4732ebe.webp" alt="Retail sentiment around IRWD trended in ‘bullish’ territory amid ‘high’ message volumes. " width="632" height="64"></figure>One user wondered whether the stock will hit the $10 mark.&nbsp;<figure class="image"><img style="aspect-ratio:667/154;" src="https://news.stocktwits-cdn.com/irwd_PNG_26af83bb21.webp" alt="One user wondered whether the stock will hit the $10 mark. " width="667" height="154"></figure>&nbsp;Shares in the IRWD fell 25.1% in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

The Linzess Room at Ironwood Pharmaceuticals in Cambridge, MA on April 20, 2018. (Photo by Craig F. Walker/The Boston Globe via Getty Images)

The company announced on Friday that it expects FY2026 revenue in the $450 million to $475 million range. 

iShares Core S&P Total U.S. Stock Market ETF

SPDR SSGA US Small Cap Low Volatility Index ETF

ProShares UltraPro Russell2000

Vanguard Russell 2000 Growth ETF

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$3.46
Prev Close	$3.50
Open	$3.50
Dividend Yield	0.00%
50-Day Moving Average	$3.94
Beta	0.91
Avg. Volume	1.76M
PE Ratio	4.51

52-Week High	$5.78
52-Week Low	$1.76
Market Capitalization	$578.34M
EPS (Annual)	$0.1474
Price to Book	-3.53
Revenue Per Employee	$2.96M

Feed

News

Sentiment

Earnings

Fundamentals

Info

IRWD Fundamentals